PROGENRA INC

Malvern, PA · Biotech · Private

Small molecule Parkin activator compounds (PACs) that promote mitophagy and mitochondrial biogenesis to prevent post-myocardial infarction heart failure

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · progenra.com

Sector: Biotech
Headquarters: Malvern, PA
Total capital: $14.6M

Federal grants: $14.6M; 33 awards · 2015–2025; Rank in peer group#219 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 4; 8 pending · first 2016; Rank in peer group#85 of 514

Capital timeline

Latest events

May 2025Federal grantHealth and Human S · Phase I · Ubiquitin pathway modulators as novel antituberculosis drugs$302K
Sep 2024Federal grantHealth and Human S · Phase I · Ubiquitin pathway modulators for treating pancreatitis$270K
Sep 2022Federal grantHealth and Human S · Phase I · Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis$255K
Apr 2022Federal grantHealth and Human S · Phase I · Parkin activators for cardioprotective therapies$297K
Mar 2022Federal grantHealth and Human S · Phase I · Parkin activators for cardioprotective therapies$297K
Sep 2021Federal grantHealth and Human S · Phase I · Novel TXNIP degraders for treating diabetes$266K
Sep 2021Federal grantHealth and Human S · Phase I · Novel TXNIP degraders for treating diabetes$266K

Show 26 earlier federal awards

Aug 2020Federal grantHealth and Human S · Phase I · Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs)$297K
Jul 2020Federal grantHealth and Human S · Phase I · Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs)$297K
Sep 2019Federal grantHealth and Human S · Phase I · Nonalcoholic Steatohepatitis Therapies from the Ubiquitin Pathway$225K
Aug 2019Federal grantHealth and Human S · Phase I · Ubiquitin E3 ligase activators for treatment of psoriasis$224K
May 2018Federal grantHealth and Human S · Phase II · Small molecule Parkin activators to treat Alzheimer's Disease$643K
Apr 2018Federal grantHealth and Human S · Phase I · Small-molecule inhibition of mechanisms shared across pathogenic cells in systemic lupus erythematosus$223K
Dec 2017Federal grantHealth and Human S · Phase II · Ubiquitin pathway inhibitors for treatment of asthma$636K
Sep 2017Federal grantHealth and Human S · Phase II · Small molecule Parkin activators to treat Alzheimer's Disease$1.4M
Aug 2017Federal grantHealth and Human S · Phase I · Small molecule ubiquitin ligase modulators for immunotherapy of cancer$225K
Aug 2017Federal grantHealth and Human S · Phase II · Small molecule Parkin activators to treat Alzheimer's Disease$741K
Jan 2017Federal grantHealth and Human S · Phase II · Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment$749K
Jan 2017Federal grantHealth and Human S · Phase II · Ubiquitin pathway inhibitors for treatment of asthma$757K
Sep 2016Federal grantHealth and Human S · Phase I · In vitro human model for individualized response to CFTR modulators$339K
Jul 2016Federal grantHealth and Human S · Phase I · A novel mechanism based therapy for cystic fibrosis$205K
Jul 2016Federal grantHealth and Human S · Phase I · Novel ubiquitin protease inhibitor for treating asthma$206K
May 2016Federal grantHealth and Human S · Phase I · Small molecule Parkin activators to treat Alzheimer's Disease$225K
Apr 2016Federal grantHealth and Human S · Phase I · Small molecule Parkin activators to treat Alzheimer's Disease$225K
Feb 2016Federal grantHealth and Human S · Phase II · Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment$749K
Feb 2016Federal grantHealth and Human S · Phase II · Chemical Optimization of a novel class of USP inhibitor for cancer treatment$1.5M
Sep 2015Federal grantHealth and Human S · Phase I · Mitophagy inhibitors for treatment of Alzheimer's Disease$205K
Aug 2015Federal grantHealth and Human S · Phase II · Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol$612K
Jul 2015Federal grantHealth and Human S · Phase II · Novel molecular therapeutics for cystic fibrosis$667K
Jun 2015Federal grantHealth and Human S · Phase I · Novel E3 ligase inhibitors for treatment of neurodegenerative disease$225K
Apr 2015Federal grantHealth and Human S · Phase II · Ubiquitin E3 ligase detection by fluorescence resonance transfer$611K
Apr 2015Federal grantHealth and Human S · Phase I · Development of novel drugs to treat obesity$223K
Apr 2015Federal grantHealth and Human S · Phase I · Development of novel drugs to treat obesity$223K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#219 · top 43%
Granted patents#85 · top 17%
Linked publications#28 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 4 granted of 12

Mar 15, 2022GrantedAzole Compounds As Ubiquitin-specific Protease USP7 InhibitorsUSPTOUS 11,273,154
May 21, 2019GrantedCovalent Irreversible Inhibitors Of USP7 As Anti-cancer AgentsUSPTOUS 10,292,973
Aug 1, 2017GrantedMethods Of Treating Cancer Through The Inhibition Of USP7 And Immune System ModulationUSPTOUS 9,717,717

Show all 12 patent records

Azole Compounds As Ubiquitin-specific Protease USP7 InhibitorsMar 15, 2022 · US 11,273,154Granted
Covalent Irreversible Inhibitors Of USP7 As Anti-cancer AgentsMay 21, 2019 · US 10,292,973Granted
Methods Of Treating Cancer Through The Inhibition Of USP7 And Immune System ModulationAug 1, 2017 · US 9,717,717Granted
Di- and Poly-Ubiquitin Deubiquitinase Substrates and Uses ThereofJul 5, 2016 · US 9,382,574Granted
Methods of Screening for Inhibitors of EnzymesOct 16, 2014 · Application 14233537Pending
Mutant Proteases And Methods Of Use ThereofOct 17, 2013 · Application 13799972Pending
Methods Of Screening For Inhibitors Of EnzymesApplication PCTUS2012056488Pending
Anti-neoplastic Compounds, Compositions And MethodsApplication PCTUS2010029358Pending
Methods Of Identifying Modulators Of Ubiquiting LigasesApplication PCTUS2009051538Pending
Covalent Irreversible Inhibitors Of USP7 As Anti-cancer AgentsApplication PCTUS2016044434Pending
Diagnostic And Screening Methods And Kits Associated With Proteolytic ActivityApplication PCTUS2005021819Pending
Azole Compounds As Ubiquitin-specific Protease USP7 InhibitorsApplication PCTUS2018020625Pending

Recent research by its founders

Clonal hematopoiesis associated with epigenetic aging and clinical outcomes20240 cites
Data from USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia20230 cites
Figures S1-17 plus legends from USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia20230 cites

SPIRA INCSimilar federal contract value in Biotech · null in contracts
FORAGR MEDICINES, INCSimilar federal contract value in Biotech · null in contracts
PROMUTECH PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
ATGC Inc.Similar federal contract value in Biotech · null in contracts
VONA THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
ASTERO ERADO INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.